Update of CVM's What's New - FDA Conditionally Approves Tanovea-CA1, the first New Animal Drug for Treating Lymphoma in Dogs

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: Update of CVM's What's New - FDA Conditionally Approves Tanovea-CA1, the first New Animal Drug for Treating Lymphoma in Dogs

FDA Conditionally Approves Tanovea-CA1, the first New Animal Drug for Treating Lymphoma in Dogs

The U.S. Food and Drug Administration today announced the conditional approval of Tanovea-CA1 (rabacfosadine for injection), the first new animal drug intended to treat canine lymphoma. Also called lymphosarcoma, lymphoma is a type of cancer in dogs. The active ingredient in Tanovea-CA1 is rabacfosadine, a substance that kills rapidly growing cancer cells.

Read more.

More Animal Health Topics

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? Please visit subscriberhelp.govdelivery.com
• Other inquiries? webmail@xxxxxxxxxx

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 1-888-INFO-FDA (1-888-463-6332)